Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients
Open accessAbstract
Introduction Rearrangements of RET are rare oncogenic events in patients with non-small cell lung cancer (NSCLC). While the characterization of Asian patients suggests a predominance of nonsmokers of young age in this genetically defined lung cancer subgroup, little is known about the characteristics of non-Asian patients. We present the results of an analysis of a European cohort of patients with RET rearranged NSCLC. Methods Nine hundred ninety-seven patients with KRAS/EGFR/ALK wildtype lung adenocarcinomas were analyzed using fluorescence in situ hybridization for RET fusions. Tumor specimens were molecularly profiled and clinicopathological characteristics of the patients were collected. Results Rearrangements of RET were identified in 22 patients, with a prevalence of 2.2% in the KRAS/EGFR/ALK wildtype subgroup. Co-occurring genetic aberrations were detected in 10 patients, and the majority had mutations in TP53. The median age at diagnosis was 62 years (range, 39-80 years; mean ± SD, 61 ± 11.7 years) with a higher proportion of men (59% versus 41%). There was only a slight predominance of nonsmokers (54.5%) compared to current or former smokers (45.5%). Conclusions Patients with RET rearranged adenocarcinomas represent a rare and heterogeneous NSCLC subgroup. In some contrast to published data, we see a high prevalence of current and former smokers in our white RET cohort. The significance of co-occurring aberrations, so far, is unclear.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
About one quarter of KRAS-mutant LUAD carry inactivating LKB1 alterations.
“Inactivating LKB1 genomic alterations, present in ~25% of KRAS-mutant LUAD”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [132]
A cohort of surgically resected early-stage LUAD reported greater NK cell buildup around KEAP1-mutant tumors.
“increased peri-tumoral accumulation of natural killer (NK) cells in KEAP1-mutant tumors was reported in a cohort of surgically resected early-stage LUAD132.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320 · see citing works
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Ports, G. D., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 958 · see citing works
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 549 · see citing works
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A. E. D. C., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P. J., Ross, J. S., Miller, V. A., Ginsberg, M. S., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 467 · see citing works
CD74–NRG1 Fusions in Lung Adenocarcinoma
Fernandez‐Cuesta, L., Plenker, D., Osada, H., Sun, R., Menon, R., Leenders, F., Ortiz‐Cuaran, S., Peifer, M., Bos, M. C. A., Daßler, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0633 · Cited by 294 · see citing works
Self-citationOncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
Doebele, R. C., Lu, X. J. D., Sumey, C. J., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 279 · see citing works
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
Tsuta, K., Kohno, T., Yoshida, A., Shimada, Y., Asamura, H., Furuta, K., & Kushima, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.36 · Cited by 200 · see citing works
Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 158 · see citing works
Dhanasekaran, S. M., Balbin, O. A., Chen, G., Nadal, E., Sundaram, S. K., Pan, J., Veeneman, B. A., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 154 · see citing works
A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
Gautschi, O. P., Zander, T., Aebersold, F., Strobel, K., Hirschmann, A., Aebi, S. P., & Diebold, J. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828a4d07 · Cited by 100 · see citing works
Self-citationMechanisms of RET signaling in cancer: Current and future implications for targeted therapy
Plaza-Menacho, I., Mologni, L., & McDonald, N. Q. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.032 · Cited by 94 · see citing works
König, K., Peifer, M., Fassunke, J., Ihle, M. A., Künstlinger, H., Heydt, C., Stamm, K., Ueckeroth, F., Vollbrecht, C., Bos, M. C. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000570 · Cited by 93 · see citing works
Self-citationGroen, R. W. J., Oud, M. E. C. M., Schilder-Tol, E. J. M., Overdijk, M. B., ten Berge, D., Nusse, R., Spaargaren, M., & Pals, S. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1322 · Cited by 45 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). A genomics-based classi- ficaton of human lung tumors. Sci Transl Med. 2013;5:209ra153.
Cited by
Sorted by citations
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works
Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284 · see citing works
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckeroth, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.013 · Cited by 264 · see citing works
Self-citation
- Authors
- Michels, S., Scheel, A. H., Scheffler, M., Schultheis, A. M., Gautschi, O., Aebersold, F., Diebold, J., Pall, G., Rothschild, S., Bubendorf, L., Hartmann, W., Heukamp, L., Schildhaus, H.-U., Fassunke, J., Ihle, M. A., Künstlinger, H., Heydt, C., Fischer, R., Nogovà, L., Mattonet, C., Hein, R., Adams, A., Gerigk, U., Schulte, W., Lüders, H., Grohé, C., Graeven, U., Müller-Naendrup, C., Draube, A., Kambartel, K.-O., Krüger, S., Schulze-Olden, S., Serke, M., Engel-Riedel, W., Kaminsky, B., Randerath, W., Merkelbach-Bruse, S., Büttner, R., & Wolf, J.
- Affiliations
- University Hospital Cologne (DE)
- Luzerner Kantonsspital (CH)
- Innsbruck Medical University (AT)
- University Hospital of Basel (CH)
- University Hospital Münster (DE)
- Universitätsmedizin Göttingen (DE)
- Johanniter-Krankenhaus Bonn (DE)
- Evangelische Lungenklinik Berlin (DE)
- Kliniken Maria Hilf (DE)
- Bethanien Krankenhaus Moers (DE)
- Lungenklinik Hemer (DE)
- Lungenklinik Köln-Merheim (DE)
- Krankenhaus Bethanien (DE)
- Corresponding author
- Wolf, Jürgen
- ORCID
- Michels, Sebastian
- Scheel, Andreas Hans
- Scheffler, Matthias
- Schultheis, Anne Maria
- Gautschi, Oliver
- Diebold, Joachim
- Pall, Georg
- Rothschild, Sacha
- Bubendorf, Lukas
- Hartmann, Wolfgang
- Heukamp, Lukas
- Schildhaus, Hans-Ulrich
- Fassunke, Jana
- Ihle, Michaela Angelika
- Heydt, Carina
- Fischer, Rieke
- Adams, Anne
- Grohé, Christian
- Graeven, Ullrich
- Draube, Andreas
- Kambartel, Karl-Otto
- Krüger, Stefan
- Randerath, Winfried
- Büttner, Reinhard
- Wolf, Jürgen
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 11
- Issue
- 1
- Pages
- 122-127
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2225799198
- Cited by
- 91
- References
- 14
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 16 · 2021: 8 · 2020: 7 · 2019: 2 · 2018: 15 · 2017: 8 · 2016: 6 · 2014: 1
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- RET fusion, non-small cell lung cancer, lung adenocarcinoma, clinicopathological features, European patients, smoking status, TP53 mutation
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Europe, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Biomarkers, Tumor, Gene Rearrangement, Oncogene Proteins, Fusion, In Situ Hybridization, Fluorescence, Proto-Oncogene Proteins c-ret
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
